Khiron Life Sciences Corp (CVE:KHRN) Director Vicente Fox Celebrates 10 Years of Cannabis Advocacy

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Vicente Fox, Independent Director for Khiron Life Sciences (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) and former Mexican President talks to James about the state of cannabis in Latin America and beyond.  He dives into the legislation within Mexico and Colombia and the readiness of Khiron to adapt to changing legal environments.  Vicente looks ahead to the future of the industry and where it’s headed, especially as it relates to more and more proven medical applications around the world.

 

**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.

 

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.

 

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

Transcript

James West: Joining me now is former president of Mexico. Mr. Vicente Fox joins me in studio. Mr. Fox, welcome.

Vicente Fox: Pleasure James and thank you for inviting me. Beautiful city Toronto, unfortunate weather.

James West: Yes. Well…

Vicente Fox: A little bit wet and cold.

James West: Story of our city, story of our summer. Señor Fox you are now an active participant in the cannabis industry and Mexico is driving towards cannabis legalization. What exactly is the status of the laws in Mexico pertaining to cannabis presently?

Vicente Fox: Okay, being an activist for 10 years now. So, it’s been a long way to get to where we are in this magnificent booming industry. What is the situation in Mexico? It’s number one, medical use has been approved about a year ago and it’s legal.  But, unfortunately we don’t yet have the regulation to operate that law. 

We had a change of government in between. The new government is just taking hold of the situation and it’s a very liberal government so has not only announced to try to move fast with regulation and medical use but also to open recreational use which will make Mexico together with Canada, the two leading nations that have approved both uses and we’ll go for the whole enchilada.

James West:Okay. So how long do you think until regulations are in place so that patients can access medical cannabis?

Vicente Fox: Regulations, I think it should be no more than maybe four no longer than eight weeks, and recreational use within the year. It will happen within the year.

James West: Okay. Is there any concern that the medical or the rather the introduction of recreational rules will catalyze a reaction from the cartels who currently control that business?

Vicente Fox: What we have experienced behind would be Colombia that did have the same situation very similar to Mexico and things went fluidly. They are operating right now on the medical use, not yet recreational. But cartels, I think that they have diversified their income so much that yes, they would be losing some income out of the cannabis space but, yet they have other criminal activities.

On the other hand, I think that what has happened with the industry in other places like Canada, like United States, those that participated in the old illegal industry at the very end join in when it became legal and now are businessmen, are salesmen, are owners of small stores. So, that’s the process. It happens that the new industry, the legal industry dominates totally over the old criminal industry.

James West: Hmm interesting. You recently hosted a conference in Mexico, in your home state of Guanajuato and it was called CannaMexico appropriately. Tell me about that conference.

Vicente Fox: Well that conference is sponsored and promoted by both of us Khiron, this company in the space of cannabis, Colombian Canadian company, which is the leading company in Latin America. 

James West: Khiron Life Sciences.

Vicente Fox: Khiron Life Sciences and Centro Fox, which is the first Presidential Library outside of United States. We run it now for the second time, 1500 top executives from all around the world, scientists, academics, governments. So, everybody participated. Our whole idea at Centro Fox together with Khiron is to promote the industry, to promote the benefits of the industry, especially the ones related to medical use and is permeating, is really people catching the whole idea that we have a nice, good booming industry. That we have already taken away this beautiful plant from the criminals, from the cartels and now, put it in hands of the business community, corporate world, government with taxes and I think everybody’s very motivated and enthusiastic about the future. 

James West: Hmm. There are different things permitted for different indications in different countries. The cannabis space medically is very confusing worldwide. Specifically to Mexico, have they limited the use of medical cannabis to just a few human ailments or have they basically broadly opened up?

Vicente Fox: It’s according to the laws, broadly open up and we’re waiting for the regulation, but I don’t think it will limit what already has been approved. So, certainly would be for everybody. Khiron is already taking positions, looking for an acquisition of clinics, which we already did in Colombia. Ilan is the name of this clinic chain that has over a hundred thousand patients. 

We’re looking in Mexico for at least a million and up to 3 million which already exists, which already are patients having to get attendance for pain in their heads, for different problems like Alzheimer’s. So, once we have those chains of patients, then you start introducing the product. 

It’s not going to be sold on the shelf. Really Khiron is very professional in this, selling a package. So, we make a diagnosis of the patient, then we determine what his needs are, then we gave him a prescription and they will go hand-by-hand to guide him to the future so that he can really cure his problems.

James West: Hmm interesting. Will Mexico permit exports? I mean, the reason I ask this is for companies like Khiron, Mexico potentially could be one of the lowest cost producers in the world. So, if there’s an export market Khiron could very much profit by that. Is that on the menu?

Vicente Fox: That is correct. You’re right. It’s not for sure right now that Mexico will allow trading, exports and imports. But Mexico’s economy is the most open economy in the world. We trade with 42 different economies. We have Trade Agreements. The most important one of them is North America. The trade agreement with Canada, United States and Mexico, which has the largest trade balance in the world, approaching a trillion U.S Dollars a year. So, a million of a million dollars every year we trade between the three economy.

I think that this industry is the same today as the automobile industry or the pharma industry will integrate to NAFTA and be part of this trading world. But, we need to wait for United States to go open on national terms, on federal terms because right now it’s state by state. But, if we have Canada and Mexico already open national and federal then United States will join in and certainly would be an excellent, excellent industry creating jobs, creating wealth and creating trade.

James West: Sure. So, the population of Mexico now is about what?

Vicente Fox: We’re about a hundred and twenty-five million.

James West: So, that’s a pretty massive market. 

Vicente Fox: It is and 80% of them are middle classes with purchasing power. 

James West: Sure. 

Vicente Fox: That’s why we’re excited. Certainly, we’ll be together with Brazil. The two largest markets in Latin America by far.

James West: Wow, so is Khiron in a position now to take advantage immediately when the regulations come into place. 

Vicente Fox: Of course, of course. We already done our job. We have offices and executives in Brazil, in Chile, in Uruguay, in Argentina, in Peru, in Colombia of course, where we have a modern state-of-the-art production source, which is going to be the most competitive cost related processing and growing the plant.

I think the cost of producing and growing in Latin America will be 30%, 40% of the cost in Canada or United States. So, this is a very competitive advantage.

James West: Sure. Do you see a future where potentially Mexico, Colombia companies like Khiron could actually dominate the global supply of cannabis as ingredients for medical products?

Vicente Fox: No doubt and that’s about to happen. It’s moving pretty fast because Khiron with its very sophisticated strategy, with its trade name and its top executives running the company has already raised a hundred million U.S. Dollars in the market and it’s investing very wisely, as I said in producing in Colombia, in acquisitions; buying companies that are already in the market place like these clinics and pharmacy places, to retail and also we have already been participating in the wellness industry with a product by the name of Kuida.

Kuida, which is a great name is now being marketed in Colombia. We’re ready to start in Mexico as soon as the regulation comes in. So yes, the company is taking positions, is investing in the marketplace, is preparing and being ready for the moment it is approved Then you move faster head and you dominate the space.

James West:  Sure. The rules in the rest of Latin America, are they more or less on pace with where Mexico and Colombia are at or is it mixed like the United States?

Vicente Fox: As you know we’re an industry and everything is new. So, you tend to take decisions by the day and you have plans but, you adapt them to whatever is happening. Now, I guess with Canada now, as the leading nation in the world on the whole spectrum of cannabis, is showing and giving us an example of how to move now in other places. Israel is the leading country technology-wise. They really have advanced technology in the medical use and the recreational use. So, everything is now getting experience. Everybody’s getting more knowledge.

And by the way, we have an agreement with Khiron and Centro Fox, which is the first Presidential Library outside of the United States, which is in the state of Guanajuatoin Mexico, which is the library I believe, we’re going to establish there a knowledge center, a research center with seminars, with a lot of information, a lot of training for the whole participants. Not only consumers, not only patients, but mostly those who are going to attend to those patients; doctors, hospitals, authorities, governments need a lot of information. 

They are taking decision without understanding the industry. So we have to have a strong PR programs to approach government, sit down with them and discuss how this industry is going to be a very successful job creation industry, wealth creation industry and in enhancing economies throughout the world It’s a new world, is a new sector of the economy, and I think it’s going to be fantastic. 

James West: Okay. Well, that’s great. I really appreciate you joining us today. Thank you very much for your input.

Vicente Fox: My pleasure, sir.  Jim, we’ll see you soon.

James West: Definitely.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Be the first to hear from Midas Letter on all things Cannabis.